secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001104659-24-108958
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European Commission grants orphan designation to VCN-01 for retinoblastoma
--------------------------------------------------------------------------

- Orphan medicinal product designation granted by European Commission for VCN-01 oncolytic adenovirus to treat retinoblastoma.
- FDA previously granted orphan drug and rare pediatric disease designations for same indication.
- Designation provides 10-year EU market exclusivity post-approval, protocol assistance, and fee reductions.
- Phase 1 trial in pediatric refractory retinoblastoma showed encouraging safety/activity with intravitreal VCN-01.
- Company working with physicians and regulators on VCN-01 as adjunct to chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924108958/0001104659-24-108958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924108958/tm2426230d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-108958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer